Tina Schubert

Dr. Tina Schubert

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2022 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
TSTina Schubert
Tina Schubert
NRNicole Reisch
Nicole Reisch
RNRonald Naumann
Ronald Naumann
IRIlka Reichardt
Ilka Reichardt
DLDana Landgraf
Dana Landgraf
KKKatrin Koehler
Katrin Koehler
Steroid 21-hydroxylase is an enzyme of the steroid pathway that is involved in the biosynthesis of cortisol and aldosterone by hydroxylation of 17α-hydroxyprogesterone and progesterone at the C21 position. Mutations in CYP21A2, the gene encoding 21-hydroxylase, cause the most frequent form of the autosomal recessive disorder congenital adrenal hyperplasia (CAH). In this study, we generated a humanized 21-hydroxylase mouse model as the first step to the generation of mutant mice with different CAH-causing mutations. We replaced the mouse Cyp21a1 gene with the human CYP21A2 gene using homologous recombination in combination with CRISPR/Cas9 technique. The aim of this study was to characterize the new humanized mouse model. All results described are related to the homozygous animals in comparison with wild-type mice. We show analogous expression patterns of human 21-hydroxylase by the murine promoter and regulatory elements in comparison to murine 21-hydroxylase in wild-type animals. As expected, no Cyp21a1 transcript was detected in homozygous CYP21A2 adrenal glands. Alterations in adrenal gene expression were observed for Cyp11a1, Star, and Cyb11b1. These differences, however, were not pathological. Outward appearance, viability, growth, and fertility were not affected in the humanized CYP21A2 mice. Plasma steroid levels of corticosterone and aldosterone showed no pathological reduction. In addition, adrenal gland morphology and zonation were similar in both the humanized and the wild-type mice. In conclusion, humanized homozygous CYP21A2 mice developed normally and showed no differences in histological analyses, no reduction in adrenal and gonadal gene expression, or in plasma steroids in comparison with wild-type littermates.

Verified
Journal Article
Open access
PDF file
STShamini Ramkumar Thirumalasetty
Shamini Ramkumar Thirumalasetty
TSTina Schubert
Tina Schubert
RNRonald Naumann
Ronald Naumann
IRIlka Reichardt
Ilka Reichardt
MRMarie-Luise Rohm
Marie-Luise Rohm
KKKatrin Koehler
Katrin Koehler
Congenital Adrenal Hyperplasia (CAH) is an autosomal recessive disorder impairing cortisol synthesis due to reduced enzymatic activity. This leads to persistent adrenocortical overstimulation and the accumulation of precursors before the blocked enzymatic step. The predominant form of CAH arises from mutations in CYP21A2, causing 21-hydroxylase deficiency (21-OHD). Despite emerging treatment options for CAH, it is not always possible to physiologically replace cortisol levels and counteract hyperandrogenism. Moreover, there is a notable absence of an effective in vivo model for pre-clinical testing. In this work, we developed an animal model for CAH with the clinically relevant point mutation p.R484Q in the previously humanized CYP21A2 mouse strain. Mutant mice showed hyperplastic adrenals and exhibited reduced levels of corticosterone and 11-deoxycorticosterone and an increase in progesterone. Female mutants presented with higher aldosterone concentrations, but blood pressure remained similar between wildtype and mutant mice in both sexes. Male mutant mice have normal fertility with a typical testicular appearance, whereas female mutants are infertile, exhibit an abnormal ovarian structure, and remain in a consistent diestrus phase. Conclusively, we show that the animal model has the potential to contribute to testing new treatment options and to prevent comorbidities that result from hormone-related derangements and treatment-related side effects in CAH patients.

24 April 2014 in European Urology Supplements
Verified
Journal Article
Closed access
TSTina Schubert
Tina Schubert
MLM.A. Laudano
M.A. Laudano
FZF. Zhao
F. Zhao
BCBilal Chughtai
Bilal Chughtai
RLR.K. Lee
R.K. Lee

24 March 2017 in European Urology Supplements
Verified
Journal Article
Closed access
TSTina Schubert
Tina Schubert
MSM.A. Schmid
M.A. Schmid
MRM. Renninger
M. Renninger
TLT. Lütfrenk
T. Lütfrenk
Arnulf StenzlArnulf Stenzl
Arnulf Stenzl
GGGeorgios Gakis
Georgios Gakis

24 March 2017 in European Urology Supplements
Verified
Journal Article
Closed access
TSTina Schubert
Tina Schubert
MSM.A. Schmid
M.A. Schmid
MRM. Renninger
M. Renninger
TLT. Lütfrenk
T. Lütfrenk
Arnulf StenzlArnulf Stenzl
Arnulf Stenzl
GGGeorgios Gakis
Georgios Gakis

11 March 2016 in European Urology Supplements
Verified
Journal Article
Closed access
GGGeorgios Gakis
Georgios Gakis
TMTodd M Morgan
Todd M Morgan
SDSiamak Daneshmand
Siamak Daneshmand
KKK.A. Keegan
K.A. Keegan
JMJ. Mischinger
J. Mischinger
JEJ. Efstathiou
J. Efstathiou